A Study of Enfortumab Vedotin in Combination With Pembrolizumab in People With Bladder Cancer of Variant Histology

Full Title

Phase II Single-Arm Study of Enfortumab Vedotin (EV) plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Samuel Funt’s office at 646-888-4770 

Protocol
26-221
Phase
Phase II (phase 2)
Investigator
Samuel A. Funt
Co-Investigators
Jonathan E. Rosenberg
Diseases
Genitourinary Cancer › Bladder Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT05756569
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description